课题基金 / 基金详情

The role of the transcriptional co-repressor RIP 140 in muscular dystrophy: a therapeutic target?

The role of the transcriptional co-repressor RIP 140 in muscular dystrophy: a therapeutic target?
转录辅阻遏物 RIP 140 在肌营养不良症中的作用:治疗靶点?
批准号:
242418
负责人:
Ljubicic Vladimir
金额:
$3.28万
依托单位:
依托单位国家:
加拿大
项目类别:
Fellowship Programs
财政年份:
2011
资助国家:
加拿大
项目状态:
已结题
起止时间:
2011-10-01 至 2012-10-01

项目摘要

项目成果

Ljubicic Vladimir的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Duchenne Muscular Dystrophy (DMD) is the most prevalent inherited neuromuscular disorder. This disease is extremely severe as children become wheelchair-bound by early adolescence and death occurs in their second or third decade of life. DMD results from
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Determining the molecular mechanisms of CARM1's role in the maintenance and plasticity of skeletal muscle mass and function
  • 批准号:
    479146
  • 项目类别:
    Operating Grants
  • 资助金额:
    $49.88万
  • 财政年份:
    2023
  • 负责人:
    Ljubicic Vladimir
  • 依托单位:
Canada Research Chair - Tier 2
  • 批准号:
    404295
  • 项目类别:
  • 资助金额:
    $36.43万
  • 财政年份:
    2018
  • 负责人:
    Ljubicic Vladimir
  • 依托单位:
Targeting AMPK to treat muscular dystrophy
  • 批准号:
    389362
  • 项目类别:
    Operating Grants
  • 资助金额:
    $36.22万
  • 财政年份:
    2018
  • 负责人:
    Ljubicic Vladimir
  • 依托单位:
AMPK-mediated neuromuscular plasticity: Implications for the treatment of neuromuscular disorders
  • 批准号:
    364110
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.1万
  • 财政年份:
    2017
  • 负责人:
    Ljubicic Vladimir
  • 依托单位:
海外基金